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Abstract: The aim of the study was to describe the epidemiologic and
clinical characteristics and identify the risk factors of short-term and
1-year mortality in a recent cohort of patients with infective endocarditis
(IE).
From January 2008, multidisciplinary teams have prospectively
collected all consecutive cases of IE, diagnosed according to the Duke
criteria, in 25 Spanish hospitals.
Overall, 1804 patients were diagnosed. The median age was 69 years
(interquartile range, 55–77), 68.0% were men, and 37.1% of the cases
were nosocomial or health care-related IE. Gram-positive microorgan-
isms accounted for 79.3% of the episodes, followed by Gram-negative
(5.2%), fungi (2.4%), anaerobes (0.9%), polymicrobial infections (1.9%),
and unknown etiology (9.1%). Heart surgery was performed in 44.2%, and
in-hospital mortality was 28.8%. Risk factors for in-hospital mortalityurgery, cerebrovascular disease, atrial fibrilla-
andida etiology, intracardiac complications,
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mortality were age (odds ratio [OR], 1.02), neoplasia (OR, 2.46), renal
insufficiency (OR, 1.59), and heart failure (OR, 4.42). Surgery was an
independent protective factor for 1-year mortality (OR, 0.44).
IE remains a severe disease with a high rate of in-hospital (28.9%)
and 1-year mortality (11.2%). Surgery was the only intervention that
significantly reduced 1-year mortality.
(Medicine 94(43):e1816)
Abbreviations: 16S rRNA PCR = 16S ribosomal RNA (rRNA)
gene polymerase chain reaction (PCR), CNS = central nervous
system, GAMES = The Spanish Collaboration on Endocarditis-
Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en
Espan˜a, ICE = International Collaboration on Endocarditis, IE =
infective endocarditis, IQR = interquartile range, IVDU =
intravenous drug users, OR = odds ratio.
INTRODUCTION
I nfective endocarditis (IE) is a severe disease with highmorbidity, and prolonged hospital stay. Mortality during the
IE admission ranges from 13% to 25%, and a further 9% to 20% of
the patients will die during the first year after discharge.1–5
Owing to the low incidence of IE (1.7–7.9 cases/100,000
inhabitants3,4,6–9), data on clinical presentation, complications,
and outcomes are mainly obtained from series collected over
prolonged periods, in single centers, or over shorter periods in
multicenter, multinational studies from selected centers.3,9–11
Consequently, they do not necessarily represent the current
situation of a whole country.
In 2008, in association with the International Collaboration
on Endocarditis (ICE),1,12 we created a national cooperative
endocarditis study group, The Spanish Collaboration on Endo-
carditis-Grupo de Apoyo al Manejo de la Endocarditis Infec-
ciosa en Espan˜a (GAMES), with the objectives of improving the
care of IE patients and conducting research in Spain.
The objective of the present study was to define the
characteristics of IE in a prospective multicenter, nationwide
study, performed in 25 centers of Spain and to identify risk
factors of early and late mortality.
MATERIALS AND METHODSPatients
The study sample comprised all consecutive patients with
IE in the 25 centers from January 1, 2008 to December 31, 2012.
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GAMES is a prospective registry performed by multidisciplin-
ary group dedicated to improve the management of IE.
Hospital-based endocarditis groups include microbiologists,
infectious disease physicians, heart surgeons, echocardiogra-
phers, imaging specialists, and cardiologists. These groups
prospectively recorded all consecutive episodes of IE at their
institutions and collected the data according to a preestablished
clinical form with common standard definitions.13–15 At dis-
charge, the clinical forms were sent to the coordinating center or
data were entered directly by the investigators through a secure
data entry system. In the coordinating center, specialized clin-
icians and data managers reviewed the data for accuracy and
contacted the referring centers, if necessary, for queries and
clarifications. Patients were followed for 1 year.
Episodes were classified into 4 distinct categories repre-
senting different populations: native valve IE in intravenous
drug users (IVDU), native valve IE in non-IVDU, prosthetic
valve IE, and IE involving implantable cardiac devices.
Definitions
IE was defined according to the modified Duke
criteria.14,16 Site of IE acquisition was defined following ICE
recommendations.13 In brief, community-acquired IE was
defined as IE diagnosed within the first 48 hours of admission
in a patient who did not fulfill the criteria for nosocomial or
health care-associated infection. Nosocomial IE was defined as
IE in a patient who had been hospitalized for >48 hours before
the onset of signs or symptoms consistent with IE. Health care-
associated IE was an IE diagnosed within 48 hours of admission
of an outpatient with any of the following criteria17: intravenous
therapy, wound care, or specialized nursing care at home within
the 30 days before the onset of IE; attendance at a hospital or
hemodialysis clinic or receipt of intravenous chemotherapy
within the 30 days before the onset of IE; hospitalization in
an acute care hospital for 2 or more days during the 90 days
before the onset of IE; or residence in a nursing home or long-
term care facility. An implantable cardiac device was defined as
a permanent pacemaker and/or cardioverter-defibrillator. Peri-
valvular extension was considered to be substantial when
abscesses were present or other echocardiography findings
suggested that the infection was invasive (communication
between chambers, wall dissection, or large valvular dehis-
cence). Prosthetic valve IE was defined as an endovascular
infection occurring on parts of a valve prosthesis or on recon-
structed native heart valves whether a mechanical prosthesis,
and/or a bioprosthetic xenograft, stented or unstented, and/or a
repaired native valve with implantation of an annular ring. The
EuroSCORE20 was used to assess operative risk.18,19 We used
the Charlson comorbidity index as a method of categorizing
comorbidities of the patients.20
Chronic immunosuppressive therapy was defined as the
administration of recognized immunosuppressive agents for
>30 days at the time of IE diagnosis.
Central nervous system (CNS) event was defined as an acute
neurological deficit of vascular etiology lasting >24 hours.21
Systemic embolization was defined as an embolic event outside
of the CNS. Congestive heart failure was defined according to the
New York Heart Association classification system.22
Statistical Analysis
The 4 classic types of IE were compared: native valve IE in
Mun˜oz et alIVDU and in non-IVDU, prosthetic valve IE, and IE affecting
intracardiac devices. Quantitative variables were expressed as
mean standard deviation or as medians with interquartile
2 | www.md-journal.comrange (IQR), as appropriate; qualitative variables were
expressed as frequency and percentage. Continuous variables
were compared using the t test, and categorical variables were
compared using the x2 test or Fisher exact test when the x2 test
was not appropriate. Adjusted odds ratios (ORs)23 were com-
puted using logistic regression analysis. Stepwise logistic
regression analysis was performed including variables with a
P value 0.1 in the univariate analysis. All statistical analyses
were performed using SPSS software version 18 (IBM PASW
Statistics 18.0, Armonk, New York, NY).
Ethics
The project and the common case report form were
approved by the national and local institutional review boards
and ethics committees (E.C. 18/07).
RESULTS
Incidence of IE
The study sample comprises total of 1804 IE cases from 25
centers, located throughout Spain. Those institutions attend an
estimated population of 10,218,634 habitants, that is, 21.7% of
the Spanish population.24 Therefore, we estimated an annual
incidence of at least 3.5 cases of IE per 100,000 inhabitants.
General Characteristics of the Cohort
The median age of the cohort was 69 years (IQR, 55–77;
mean, 65.1), and 1228 (68.0%) patients were male. The most
common ‘‘extracardiac underlying conditions’’ are shown in
Table 1. The main comorbidities were diabetes mellitus (471,
26.1%), pulmonary disease (312, 17.3%), and neoplasm (290,
16.1%). Other comorbidities that were not as frequent, but
nevertheless had a high impact on clinical course were, hemo-
dialysis (79, 4.4%), HIV infection (39, 2.2%), and transplan-
tation (27, 1.5%). The mean Charlson-age corrected
comorbidity index was 4.49 2.6. The most common ‘‘predis-
posing heart conditions’’ were native valve disease (41.8%)
(degenerative [27%]; rheumatic valve disease [8.0%]; and
congenital heart disease [3.2%]), followed by previous valve
surgery (34.4%) and previous IE episode (6.9%).
Affected Valve
Most of the patients (62.7%) had native valve IE, and most
episodes were left-sided (mitral 808 [44.8%], aortic 852
[47.2%]). The tricuspid valve was involved in 99 cases
(5.5%) and the pulmonary valve in 29 cases (1.6%). Prosthetic
valve endocarditis occurred in 504 cases (27.9%) and device-
related endocarditis in 169 patients (9.3%).
The ‘‘site of acquisition’’ was determined in 95.9% of
patients (Table 1); 28.1% episodes were classified as noso-
comial. In the case of community-acquired episodes, most
patients (86%) were admitted within 1 month of the initial
signs of illness (12.6% at 1–3 months and 6.3% >3 months).
The ‘‘source of the infection’’ was suspected in 842 (46.6%)
patients (vascular 305; gastrointestinal 127; skin and soft tissue
124; odontogenic 115; urinary 88; respiratory 21; others 62).
‘‘Clinical manifestations’’ are shown in Table 1. It is
noteworthy that the classic signs of IE were uncommon. These
included splenomegaly (11.6%), splinter hemorrhages (2.3%),
Janeway spots (2.4%), and Osler nodes (1.9%). However,
Medicine  Volume 94, Number 43, October 2015patients with IE had other common manifestations (respiratory
[41%], renal [39%], neurological [19.7%], osteoarticular
[11.5%], and ocular [6.3%]).
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Epidemiological and Clinical Characteristics of 1804 Episodes of Infective Endocarditis Prospectively Collected in Spain
Total
N¼ 1804
Native Non-IVDU
N¼ 1079
Native IVDU
N¼ 52
Prosthetic
N¼ 504
Device
N¼ 169 P
Median age (IQR) 69 (57–77) 68.7 (55–77) 39.9 (33–45) 71.1 (61–77) 71.4 (60–78) <0.01
Male (%) 1228 (68.1) 728 (67.5) 42 (82.4) 337 (67.0) 121 (71.6) 0.10
Underlying conditions
Charlson-age index 4.49 (2.6) 4.46 2.92 4.57 4.92 <0.01
Diabetes mellitus 471 (26.1) 289 (26.8) 1 (1.9) 131 (26.0) 50 (29.8) <0.01
Mild renal insufficiency 188 (10.4) 88 (8.2) 1 (2.0) 70 (14.0) 29 (17.3) <0.01
Severe renal insufficiency 280 (15.5) 168 (15.7) 5 (9.8) 73 (14.5) 34 (20.1) 0.22
Pulmonary disease 312 (17.3) 189 (18.0) 2 (3.9) 90 (18.2) 31 (18.9) 0.07
Neoplasm 290 (16.1) 203 (18.9) 0 69 (13.7) 18 (10.7) <0.01
HIV infection 39 (2.2) 13 (1.2) 23 (44.2) 3 (0.6) 0 <0.01
Risk factors
Previous cardiac surgery 620 (34.4) 95 (8.9) 1 (2.0) 504 (100)

36 (21.4) <0.01
Previous IE 126 (7.0) 43 (4.0) 6 (11.5) 64 (12.8) 13 (7.8) <0.01
Heart failure 531 (29.4) 252 (23.6) 0 203 (40.7) 76 (46.3) <0.01
Atrial fibrillation 457 (25.3) 190 (17.9) 0 219 (44.4) 48 (29.1) <0.01
Site of acquisition
Nosocomial 507 (28.1) 241 (23.1) 1 (1.9) 190 (39.7) 75 (46.9) <0.01
Community-acquired 1061 (58.8) 701 (67.3) 49 (94.2) 251 (52.6) 60 (37.7) <0.01
Health care-related 162 (9.0) 100 (9.6) 2 (3.8) 36 (7.5) 24 (15.1) 0.01
Transferred from other hospital 479 (26.6) 281 (26.0) 13 (25.0) 139 (27.6 46 (27.2) 0.91
Symptoms before admission
(median days; IQR)
21 (7–60) 14 (5–55) 7 (4–21) 7 (3–21) 8 (5–60) 0.58
Affected valve
Aortic 852 (47.2) 499 (46.2) 13 (25.0) 327 (64.8) 13 (7.7) <0.01
Mitral 808 (44.8) 579 (53.7) 14 (26.9) 211 (41.9) 4 (2.4) <0.01
Tricuspid 99 (5.5) 58 (5.4) 24 (46.2) 4 (0.8) 13 (7.7 <0.01
Pulmonary 29 (1.6) 16 (1.5) 3 (5.8) 8 (1.6) 2 (1.2) 0.11
Presentation
Fever >388C 1506 (83.4) 899 (84.0) 43 (84.3) 427 (85.9) 137 (82.0) 0.01
Splinter hemorrhages 41 (2.3) 34 (11.0) 4 (16.0) 3 (2.7) – 0.01
Osler nodes 35 (1.9) 27 (8.4) 2 (7.7) 6 (5.0) – 0.38
Janeway lesions 43 (2.4) 29 (9.5) 4 (16.0) 9 (8.0) 1 (6.3) 0.63
Roth spots 18 (1.0) 13 (4.5) 1 (4.0) 4 (3.8) – 0.84
Splenomegaly 209 (11.6) 140 (13.7) 16 (31.4) 46 (9.5) 7 (4.3) <0.01
New murmur 577 (32.0) 430 (44.8) 23 (50.0) 115 (26.4) 9 (5.7) <0.01
Worsening of old murmur 221 (12.3) 138 (16.3) 2 (4.7) 74 (18.4) 7 (4.5) <0.01
Mean CRP (SD) 61.5 (87.2) 65.8 (90.2) 37.2 (68.0) 55.2 (84.9) 60.9 (79.1) 0.015
Elevated RF 160 (8.9) 104 (25.8) 5 (26.3) 33 (17.8) 18 (26.1) 0.18
CRP¼C-reactive protein, HCR¼ health care-related, IE¼ infective endocarditis, IQR¼ interquartile range, IVDU¼ intravenous drug users,
RF¼ rheumatoid factor, SD¼ standard deviation.
2.8% of patients with prosthetic valve developed the infectious endocarditis during the same hospital admission of the first valve surgery.
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Most episodes (79.3%) were caused by Gram-
positive microorganisms, followed by Gram-negative micro-
organisms (5.2%), fungi (2.4%), anaerobes (0.9%), and
polymicrobial infections (1.9%). The distribution of the most
common microorganisms is shown in Table 2. Twenty-two
episodes were caused by microorganisms of the HACEK
group. Other fastidious microorganisms included Coxiella
burnetii (15), Listeria monocytogenes (6), Tropheryma whip-
plei (5), Bartonella spp. (4), and Brucella melitensis (1).
Accordingly, the rate of unknown etiology of endocarditis
was 9.1%.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.Diagnosis
Blood cultures were obtained in 1787 patients (99.1%) and
provided the etiology in 1523 (85.3%). Of the 264 patients
(14.7%) with negative blood cultures, 34% had received anti-
microbial agents in the previous week. An etiologic diagnosis
was achieved in 106 cases with a combination of the following
techniques: sequence analysis of the 16S ribosomal RNA
(rRNA) gene polymerase chain reaction (PCR) 66, 25% (heart
valve 56, 21.2%; blood 8, 3.0%; and cardiac device 5, 1.9%);
serology 99, 37.5%; and extracardiac cultures 59, 22.3%.
Transesophageal echocardiography was done in most patients
(76.3%), and 1148 (83.4%) presented vegetations. Abscess was
www.md-journal.com | 3
TABLE 2. Etiology, Diagnosis, and Outcome of 1804 Episodes of Infective Endocarditis Prospectively Collected in Spain
Total
N¼ 1804
Native Non-IVDU
N¼ 1079
Native IVDU
N¼ 52
Prosthetic
N¼ 504
Device
N¼ 169 P
Definite IE 1498 (83.0) 919 (85.6) 48 (92.3) 409 (81.3) 122 (72.2) <0.01
Possible IE 300 (16.6) 155 (14.4) 4 (7.7) 94 (18.7) 47 (27.8) <0.01
Etiology
Staphylococcus spp. 728 (40.3) 382 (35.3) 30 (55.8) 218 (43.2) 98 (58.0) <0.01
S. aureus 426 (23.6) 278 (25.8) 26 (50.0) 77 (15.3) 45 (26.6) <0.01
MSSA 360 (84.5) 235 (84.5) 24 (92.3) 64 (83.2) 37 (82.3) 0.46
MRSA 66 (15.5) 43 (15.5) 2 (7.7) 13 (16.8) 8 (17.7)
CoNS 302 (16.7) 104 (9.7) 4 (7.7) 141 (28.0) 53 (31.5) <0.01
Streptococcus spp. 440 (24.4) 329 (30.5) 8 (15.4) 86 (17.1) 17 (10.1) <0.01
S. bovis 117 (6.4) 80 (7.4) 0 32 (6.5) 5 (3.0) 0.036
S. viridans group 223 (12.3) 171 (16.0) 7 (13.5) 38 (7.5) 7 (4.1) <0.01
Others 100 (5.5) 79 (7.3) 1 (1.9) 15 (3.0) 5 (5.3) 0.001
Enterococcus spp. 230 (12.7) 142 (13.2) 5 (9.6) 77 (15.3) 6 (3.6) 0.001
Other Gram-positives

26 (1.4) 14 (1.3) 2 (3.8) 8 (1.5) 2 (1.1) 0.48
Gram-negatives

93 (5.2) 53 (4.9) – 25 (5.0) 15 (8.9) 0.05
Fungi

44 (2.4) 21 (1.9) 2 (3.8) 15 (3.0) 6 (3.6) 0.38
Negative BC 264 (14.7) 152 (14.0) 5 (9.6) 75 (14.8) 32 (18.9) 0.67
Echocardiogram
TEE 1377 (76.3) 776 (72.0) 23 (44.2) 450 (89.3) 128 (76.2) <0.01
Vegetations 1284 (71.2) 836 (77.6) 41 (78.8) 296 (58.8) 111 (65.7) <0.01
Intracardiac complication 501 (27.8) 309 (28.9) 9 (17.6) 171 (33.9) 12 (7.1) <0.01
Clinical course
Embolisms 525 (29.1) 322 (30.5) 30 (60.0) 143 (28.9) 30 (18.2) <0.01
New heart failure 698 (38.7) 488 (45.9) 15 (29.4) 214 (43.2) 32 (19.2) <0.01
Persistent bacteremia 151 (8.4) 90 (8.6) 1 (2.0) 45 (9.2) 15 (9.0) 0.37
Surgery
Indicated (%) 1152 (63.9) 661 (61.4) 25 (48.1) 341 (67.7) 125 (74.0) <0.01
Performed (%) 797 (44.2) 452 (41.9) 15 (28.8) 220 (43.8) 110 (65.1) <0.01
Criteria for surgery
Cardiac insufficiency 373 (20.7) 257 (25.9) 6 (13.0) 104 (22.3) 6 (3.7) <0.01
Early prosthetic IE 67 (14.4) – – 67 (14.4) – <0.01
Late prosthetic IE 74 (15.9) – – 74 (15.9) – <0.01
Valvular insufficiency 315 (17.5) 225 (22.7) 11 (23.9) 78 (16.8) 1 (0.6) <0.01
Embolisms 50 (2.7) 35 (3.2) 3 (5.7) 10 (1.9) 2 (1.2) 0.11
Persistent bacteremia 53 (2.9) 30 (2.8) – 13 (2.6) 10 (5.9) 0.09
Outcome
Median hospital stay (IQR) 36 (21–53) 36 (21–51) 36 (22–48) 39 (18–54) 34 (23–53) 0.92
In-hospital mortality (%) 521 (28.9) 301 (27.9) 8 (15.4) 184 (36.5) 28 (16.6) <0.01
1-y mortality (%) 116 (9.1) 81 (10.4) 1 (2.27) 29 (9.0) 5 (3.5) 0.05
BC¼ blood cultures, CoNS¼ coagulase-negative staphylococci, TEE¼ transesophageal echocardiogram, IE¼ infective endocarditis,
IQR¼ interquartile range, IVDU¼ intravenous drug users, MRSA¼methicillin-resistant S. aureus, MSSA¼methicillin-sensitive S. aureus.
Other Gram-positives: Abiotrophia 9, Corynebacterium 6, Gemella 8, Listeria 3.
Gram-negatives: Acinetobacter 2, Actinobacillus 4, Alcaligenes 1, Bartonella 4, Brucella 1, Campylobacter 3, Cardiobacterium 2, Coxiella 15,
, N
1.
Mun˜oz et al Medicine  Volume 94, Number 43, October 2015the most common paravalvular complication (27.8%), whereas
Enterobacter 3, Escherichia 13, Haemophilus 7, Klebsiella 3, Moraxella 1
1, Tropheryma 5, Yersinia 1.
Fungi: Aspergillus 5, Scedosporium 1, Candida 37, Rhodotorula26.6% of patients with prosthetic valve IE had evidence of a
prosthetic valve complication such as dehiscence or new
paravalvular regurgitation.
COMPARISON OF THE 4 TYPES OF IENon-IVDU Patients With Native Valve IE
Most of the patients in our series (59.8%) were non-IVDU,
which is therefore the most heterogeneous group. Although it is
4 | www.md-journal.comdifficult to identify one characteristic that stands out, these
patients presented less frequently history of heart failure
(23.6%) or renal failure (23.9%). Most cases were com-
munity-acquired, and Streptococcus spp. was the most common
pathogen involved.
‘‘Native valve IE in IVDU’’ accounted for the smallest
group of our series. Native valve IE affected significantly
younger patients with fewer comorbid conditions, except in
eisseria 2, Pseudomonas 11, Salmonella 3, Serratia 2, Stenotrophomonasthe case of HIV infection (44.2%). Acquisition was nosocomial
in only 1.9% of the cases and, interestingly, half of these
patients had left-sided IE. A typical clinical presentation was
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
more evident in this population including splinter hemorrhages
(16%) and splenomegaly (31.4%). Staphylococcus aureus pre-
dominated as the etiological microorganism (53.8%), and
embolisms were frequent (60.0%). Outcome was clearly better
in this group.
Prosthetic Valve IE
The highest in-hospital mortality was recorded in patients
with prosthetic valve IE (36.5%, P< 0.01); however, it is of
even greater concern that infection was nosocomial in 39.7% of
these patients. Coagulase-negative staphylococci accounted for
28.0% of the cases. Accordingly, intracardiac complications
were significantly more frequent (33.9%).
Cardiac Device IE
Patients with heart devices were older, with the highest
comorbidity index and a great part were nosocomial or health
care-related IE (62%). The device involved was surgically
removed in 65.1% of the cases.
Short-Term and Long-Term Risk Factors for
Mortality
Table 3 shows a comparison of the patients who survived
(71.1%) and those who died (28.9%) during admission; Table 4
shows the independent risk factors associated with a higher risk
of in-hospital death. Independent mortality risk factors could be
grouped as epidemiological characteristics of the patient, endo-
carditis etiology (Staphylococcus spp. [OR, 2.34], fungi [OR,
3.12]) and complications (intracardiac complication [OR, 1.67],
heart failure [OR, 2.97], and septic shock [OR, 5.18]).
Independent risk factors for 1-year mortality are shown in
Table 5, and include increasing age (OR, 1.02), neoplasm (OR,
2.46), renal insufficiency (OR, 1.59), and heart failure (OR,
4.42). Surgery was independently associated with a decreased
risk of 1-year mortality (OR, 0.44) and was the only factor
amenable of intervention.
DISCUSSION
Our very large series, collected from different institutions
in a single country over a short period of time, shows that IE is
mainly a disease of the elderly, with multiple predisposing
conditions, frequently nosocomial, and has still a very high
mortality, both during admission and during the 1-year follow-
up.
Incidence rates of IE have been collected over long periods
of time, and data based on population studies are scarce. In our
series, including population-based studies of endocarditis
recruited from 1960 to 2008, incidence rates range from 3 to
10 cases/100,000 habitants,4,6–9 and our figure of 3.5 IE cases/
100,000 habitants is concordant with that. The advantage of our
series is its large dimension collected over a short period.
The underlying conditions of patients with IE have also
drastically changed,3,4,7 and most of our cases presented with
severe comorbid conditions. This population of fragile patients
is frequently exposed to health care-related and nosocomial
complications. In our series, 28% of the episodes were classified
as nosocomial; this percentage is similar to that reported by
Fernandez-Hidalgo et al.25
Clinical presentation of the disease has also changed, and
Medicine  Volume 94, Number 43, October 2015the signs that were once typical of IE (splinter hemorrhages,
Janeway lesions, and Osler nodes) are now only seen in 2% of
the patients. One possible explanation is that IE patients are now
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.diagnosed earlier (86% were admitted 1 month of the initial
signs of illness), thus reducing the incidence of immunological
manifestations.1 On the contrary, we commonly observed com-
plications such as respiratory manifestations (41%), kidney
failure (39%), neurological events (19.7%), osteoarticular
symptoms (11.5%), and ocular manifestations (6.3%). The rate
of embolic events in our series was 29%, and although our
results are similar to the ones reported by others,1,26 we believe
that this figure could be underestimated, as the extension study
depends on the institutional protocol and the technology avail-
able in each center. The introduction of newer diagnostic
imaging tools such as positron emission tomography–computed
tomography as part of the diagnostic algorithm in patients with
IE, as suggested by Saby et al,27 should prove to be of great
interest in this field.
A shift in the type of patient with IE has been observed: one
major change in our series was the very low proportion of IE
now occurring in IVDU. In Spain, this is probably related with
the programs to control IVDUs and particularly the methadone
maintenance program.28 Although historically native valve IE
in IVDU represented an important number of affected
patients,29 in our series this population accounted for the
smallest group while the number of patients with prosthetic
valve and device IE (37%), on the other hand, seems to be
increasing.4,9
Microbiological diagnostic tools have changed and
improved over recent decades, and although etiology was
confirmed by blood culture in most cases (85%), there are still
cases in which the etiology is unknown (9%). Molecular
techniques such as 16S rRNA PCR of the heart valves enabled
us to establish the etiology in 21% of the negative blood culture
episodes that would otherwise have been considered IE of
unknown etiology. However, even though molecular methods
have been used to diagnose IE, are long time, well-known
methods,30 this diagnostic approach is still not routinely avail-
able in all diagnostic laboratories.
The most common microorganisms in our series were
staphylococci, streptococci, and enterococci. Thus, a major
change in the microbiology of IE is that Enterococcus spp.
has emerged as the third most important group of pathogens and
is now causative of 13% of IE cases. Because enterococci have
shown the ability to develop antibiotic resistance,31 further
studies are needed to evaluate novel approaches to this increas-
ingly frequent problem32 and specially to identify factors
that enable the early selection of patients who are at risk for
Enterococcal IE.33
As for mortality, IE is a severe disease with a poor out-
come. In our series, in-hospital mortality was 29%, and it seems
that IE mortality has remained close to 25% since the 1970s3
despite the introduction of broad-spectrum antibiotics and new
diagnostic tools. This is probably related with the increase in
age and comorbidity. Although it is a complex procedure and it
is not free of complications, surgery, when indicated, seems to
have a major impact on mortality. In our experience, surgery
was independently associated with a decreased risk of 1-year
mortality (OR, 0.44); our results agree with those of a recent
analysis of published studies34,35 that shows a significant
correlation between the rate of early surgery and mortality.
Study Limitations
Our series may not represent the situation of IE in other
Infective Endocarditiscountries where levels of health care differ from those of Spain
(public run universal health care), but in our opinion represents
well the situation in many western countries.
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discharge remains disappointedly high. Multidisciplinary teams
TABLE 3. Risk Factors for In-Hospital Mortality
Alive N¼ 1283 Dead N¼ 521 P
Median age (IQR) 67.6 (53.7–76) 73 (62.9–78.9) <0.01
Male 907 (70.7) 321 (61.8) <0.01
Underlying condition
Heart failure 326 (25.6) 205 (40.0) <0.01
Previous cardiac surgery 411 (32.4) 209 (40.4) 0.001
Diabetes mellitus 294 (22.9) 177 (34.1) <0.01
Mild renal insufficiency 117 (9.2) 71 (13.8) 0.004
Severe renal insufficiency 163 (12.8) 117 (22.7) <0.01
Atrial fibrillation 288 (22.8) 169 (33.2) <0.01
Lung disease 209 (16.7) 103 (20.4) 0.067
Neoplasm 199 (15.5) 91 (17.5) 0.296
HIV infection 29 (2.3) 10 (2.0) 0.675
Previous IE 101 (7.9) 25 (4.8) 0.020
Charlson-age comorbidity (SD) 4.1 (2.5) 5.4 (2.5) <0.01
Transferred from other hospital 340 (26.5) 139 (26.7) 0.938
Symptoms before admission (median days [IQR]) 6 (1–18) 2 (0–8) <0.01
Affected valve
Aortic 594 (46.3) 258 (49.5) 0.214
Mitral 541 (42.2) 267 (51.2) <0.01
Tricuspid 80 (6.2) 19 (3.6) 0.029
Pulmonary 22 (1.7) 7 (1.3) 0.570
Proven endocarditis 1054 (82.3) 444 (85.9) 0.064
Possible endocarditis 227 (17.7) 73 (14.1) 0.064
Etiology (%)
S. aureus 237 (18.5) 189 (36.5) <0.01
Methicillin-resistant S. aureus 34 (2.7) 32 (6.1) <0.01
Coagulase-negative staphylococci 201 (15.7) 101 (19.4) 0.058
Streptococcus spp. 371 (28.9) 69 (13.2) <0.01
Enterococcus spp. 177 (13.8) 53 (10.2) 0.037
Other Gram-positive microorganisms 19 (1.5) 7 (1.3) 0.824
Gram-negative microorganisms 76 (5.9) 17 (3.3) 0.021
Fungi 25 (2.0) 19 (3.6) 0.034
Negative blood cultures 110 (8.6) 54 (10.4) 0.230
Vegetation 887 (69.1) 397 (76.5) 0.002
Intracardiac complication 310 (24.3) 191 (37.0) <0.01
Transesophageal echocardiogram 1004 (78.3) 375 (71.9) <0.01
Persistent bacteremia 69 (5.5) 82 (16.7) <0.01
Heart surgery
Indicated 728 (56.8) 424 (81.4) <0.01
Operated on 598 (46.7) 199 (38.2) 0.001
Reasons for surgery (%)
Cardiac insufficiency 254 (21.5) 119 (24.5) 0.185
Early prosthetic IE 47 (4.0) 31 (6.4) 0.036
Late prosthetic IE 46 (3.9) 32 (6.6) 0.019
Valvular insufficiency 245 (20.8) 70 (14.4) 0.003
Median hospital stay (IQR) 41 (27–55) 23 (11–42) <0.01
BC¼ blood cultures, IE¼ infective endocarditis, IQR¼ interquartile range, SD¼ standard deviation, TEE¼ transesophageal echocardiogram.
Mun˜oz et al Medicine  Volume 94, Number 43, October 2015In conclusion, well inside the XXI century, IE, collected in
a large number of institutions in a western country, remains an
uncommon but devastating infectious disease. It commonly
affects elderly patients with severe comorbidities, is frequently
nosocomially acquired, and may be underdiagnosed if only
suspected in the presence of classic clinical signs or typical
microorganisms bacteremia. Surgery seems the only clear
protective intervention and mortality within 1 year after
6 | www.md-journal.comare essential to optimize the management and outcome of this
severe disease.ACKNOWLEDGMENT
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TABLE 4. Independent Risk Factors for In-Hospital Mortality
Factor OR 95% CI P
Age 1.02 1.01–1.03 <0.01
Immunosuppressive therapy 2.61 1.68–4.04 <0.01
Previous heart surgery (previous
to the episode of IE)
1.53 1.17–2.00 .002
CNS event 2.47 1.91–3.19 <0.01
Atrial fibrillation 1.45 1.09–1.93 .011
S. aureus 2.34 1.75–3.12 <0.01
Fungi 3.12 1.50–6.49 .002
Intracardiac complication 1.67 1.30–2.14 <0.01
Heart failure 2.97 2.30–3.83 <0.01
Septic shock 5.18 3.62–7.40 <0.01
CI¼ confidence interval, CNS¼ central nervous system, IE¼
infective endocarditis, OR¼ odds ratio.
TABLE 5. Independent Risk Factors for 1-Year Mortality
Factor OR 95% CI P
Age 1.02 1.00–1.03 0.005
Neoplasm 2.46 1.57–3.86 <0.01
Surgery 0.44 0.286–0.694 <0.01
Renal insufficiency 1.59 1.04–2.42 0.030
Heart failure 4.42 1.06–18.40 0.041
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